Teva Pharmaceutical Industries revenue and financials
$39.13Change from previous close: −1.34%Absolute change: −$0.53
In the fiscal year ended December 2025, Teva Pharmaceutical Industries reported revenue of $17.26B (+4.32% year over year). Net income was $1.41B, a net margin of 8.2%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +4.32%
- 2025 vs 2024
- Net margin
- 8.2%
- 2024: -9.9%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Total revenue | 4,142 | 3,981 | 4,711 | 4,480 | 4,176 | — |
| Cost of revenue | 1,989 | 2,011 | 2,056 | 2,176 | 2,074 | — |
| Gross profit | 2,153 | 1,972 | 2,656 | 2,304 | 2,102 | — |
| Selling, general and administrative | 1,034 | 1,000 | 1,120 | 973 | 959 | — |
| Research and development | 970 | 222 | 267 | 256 | 244 | — |
| Operating income | 149 | 759 | 1,269 | 1,075 | 899 | — |
| EBIT | -260 | 638 | 372 | 855 | 406 | — |
| EBITDA | -19.0 | 877 | 632 | 1,104 | 657 | — |
| Interest expense | 195 | 201 | 292 | 209 | 203 | — |
| Pre-tax income | -455 | 437 | 80.0 | 646 | 203 | — |
| Income tax | 121 | 67.0 | -390 | 214 | -78.0 | — |
| Net income | -576 | 369 | 480 | 433 | 282 | — |
| Net income to common shareholders | -576 | 369 | 480 | 433 | 282 | — |
| Basic EPS | -0.49 | 0.32 | 0.42 | — | 0.25 | 0.19 |
| Diluted EPS | -0.49 | 0.31 | 0.41 | — | 0.24 | 0.18 |
| Average shares (basic) | 1,165 | 1,156 | 1,149 | — | 1,147 | 1,159 |
| Average shares (diluted) | 1,165 | 1,179 | 1,173 | — | 1,161 | 1,159 |